Durable remission after treatment with very low doses of imatinib for FIP1L1-PDGFRα-positive chronic eosinophilic leukaemia

By Helbig Grzegorz   Moskwa Andrzej   Hus Marek   Piszcz Jarosław   Swiderska Alina   Urbanowicz Alina   Całbecka Małgorzata   Seferyńska Ilona   Raźny Małgorzata   Rodzaj Marek   Żuk Ewa   Kyrcz-Krzemień Sławomira  

Cancer Chemotherapy and Pharmacology, Vol. 67, Iss. 4, 2011-04 ,pp. : 967-969

Springer Publishing Company

Access to resources Recommend Favorite

Sorafenib is effective for imatinib-resistant FIP1L1/PDGFRA T674I mutation-positive acute myeloid leukemia with eosinophilia

By Al-Riyami Arwa Z.  

Leukemia and Lymphoma, Vol. 54, Iss. 8, 2013-08 ,pp. : 1788-1790

Informa Healthcare

Access to resources Recommend Favorite

Isolated central nervous system relapse in patient with blast-crisis chronic myeloid leukemia in durable complete cytogenetic remission on dasatinib treatment: pharmacokinetics and ABL mutation analysis in cerebrospinal fluid

By Zhou Hong-Sheng   Dai Min   Wei Yongqiang   Wang Qiang   Xu Na   Yin Changxin   Meng Fanyi  

Leukemia and Lymphoma, Vol. 54, Iss. 7, 2013-07 ,pp. : 1557-1559

Informa Healthcare

Access to resources Recommend Favorite

Apoptosis- and differentiation-inducing activities of jacaric acid, a conjugated linolenic acid isomer, on human eosinophilic leukemia EoL-1 cells

By    

Oncology Reports, Vol. 32, Iss. 5, 2014-01 ,pp. : 1881-1888

Spandidos Publications

Access to resources Recommend Favorite

Chronic Eosinophilic Leukemia, Not Otherwise Specified (CEL, NOS)

By  

Current Cancer Therapy Reviews, Vol. 8, Iss. 1, 2012-02 ,pp. : 30-34

Bentham Science Publishers

Access to resources Recommend Favorite